Using a TGFB1-inducible SMAD- responsive promoter for MSC-mediated NIS gene therapy in combination with external beam radiation dramatically increased the therapeutic efficacy of NIS gene therapy with complete tumor remission seen in a subset of mice 41. This evidence concerns the gene TGFB1 and neoplasm.